Cargando…

Lamin B1 regulates somatic mutations and progression of B-cell malignancies

Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA sequence and diversify their antigen receptors. Here, we report that genome binding of Lamin B1, a component of the nuclear envelope involved in epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Klymenko, T, Bloehdorn, J, Bahlo, J, Robrecht, S, Akylzhanova, G, Cox, K, Estenfelder, S, Wang, J, Edelmann, J, Strefford, J C, Wojdacz, T K, Fischer, K, Hallek, M, Stilgenbauer, S, Cragg, M, Gribben, J, Braun, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808072/
https://www.ncbi.nlm.nih.gov/pubmed/28804121
http://dx.doi.org/10.1038/leu.2017.255
Descripción
Sumario:Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA sequence and diversify their antigen receptors. Here, we report that genome binding of Lamin B1, a component of the nuclear envelope involved in epigenetic chromatin regulation, is reduced during B-cell activation and formation of lymphoid germinal centres. Chromatin immunoprecipitation-Seq analysis showed that kappa and heavy variable immunoglobulin domains were released from the Lamin B1 suppressive environment when SHM was induced in B cells. RNA interference-mediated reduction of Lamin B1 resulted in spontaneous SHM as well as kappa-light chain aberrant surface expression. Finally, Lamin B1 expression level correlated with progression-free and overall survival in chronic lymphocytic leukaemia, and was strongly involved in the transformation of follicular lymphoma. In summary, here we report that Lamin B1 is a negative epigenetic regulator of SHM in normal B-cells and a ‘mutational gatekeeper’, suppressing the aberrant mutations that drive lymphoid malignancy.